Genomic newborn screening: ICoNS
Gene: GLAAge of onset: Variable,
Classic form 4-8 yrs, late-onset variants >25 yrs
Specifically difficult to predict in females
Treatment:
- Agalsidase-β (Recombinant α-GAL)
- Agalsidase-α (Recombinant α-GAL)
- Migalastat (Binds reversibly to the active site of the amenable mutant of α-GAL)
- Investigational therapies
Effect of (early) treatment:
There is no consensus when to start with ERT
Penetrance:
Prevalence: Prevalence in white male populations has been linked to Fabry disease in a wide range, approximately 1:17,000 to 1:117,000. Classic Fabry disease mutations are seen in approximately 1:22,000 to 1:40,000 males, and atypical presentations are associated with about 1:1000 to 1:3000 males and 1:6000 to 1:40,000 females. Although it is an under-diagnosed condition, the disease is seen in all racial and ethnic groups. (PMID: 28613767)
Sources: ClinGen, LiteratureCreated: 23 Oct 2025, 10:01 p.m.
Mode of inheritance
X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)
Phenotypes
Fabry disease (MIM 301500); Fabry disease, cardiac variant (MIM 301500)
Publications
Mode of pathogenicity
Loss-of-function variants (as defined in pop up message) DO NOT cause this phenotype - please provide details in the comments
gene: GLA was added gene: GLA was added to Genomic newborn screening: ICoNS. Sources: ClinGen,Literature Mode of inheritance for gene: GLA was set to X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males) Publications for gene: GLA were set to 28613767; 37259462 Phenotypes for gene: GLA were set to Fabry disease (MIM 301500); Fabry disease, cardiac variant (MIM 301500) Penetrance for gene: GLA were set to Complete Mode of pathogenicity for gene: GLA was set to Loss-of-function variants (as defined in pop up message) DO NOT cause this phenotype - please provide details in the comments